Abiraterone Acetate Tablet
Product Images NDC 60219-1754

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 60219-1754). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Abiraterone Acetate Tablets Usp 250 mg 500 mg 1)

Chemical structure of abiraterone, the active ingredient in ABIRATERONE ACETATE human prescription tablets. The structure features multiple fused rings with methyl groups and a pyridine ring, representing the molecular framework of abiraterone.*

FDA Label Image

2 (Abiraterone Acetate Tablets Usp 250 mg 500 mg 2)

A survival curve chart comparing percentage survival over time in months between Abiraterone Acetate and Placebo groups. The x-axis represents time to death in months, and the y-axis shows percentage survival. The chart includes two lines: a solid line for Abiraterone Acetate and a dashed line for Placebo, with survival rates decreasing over approximately 21 months.*

FDA Label Image

3 (Abiraterone Acetate Tablets Usp 250 mg 500 mg 3)

A Kaplan-Meier survival curve chart showing the percentage of subjects without death over time in months from randomization. The chart compares two groups labeled as Abiraterone Acetate and Placebo, with survival percentages on the Y-axis (ranging from 0 to 100%) and time in months on the X-axis (ranging from 0 to 60 months). Number of subjects at risk for each time interval is listed below the X-axis for both groups.*

FDA Label Image

4 (Abiraterone Acetate Tablets Usp 250 mg 500 mg 4)

A Kaplan-Meier survival curve chart comparing the percentage of subjects without radiographic progression or death over months from randomization between Abiraterone Acetate and placebo groups. The x-axis shows months from 0 to 18, and the y-axis indicates the percentage of subjects without event from 0% to 100%. Numerical subject counts at various time points for both groups are displayed below the x-axis.*

FDA Label Image

5 (Abiraterone Acetate Tablets Usp 250 mg 500 mg 5)

A Kaplan-Meier survival curve chart showing the percentage of subjects without death over months from randomization for two groups: Abiraterone acetate and placebo. The X-axis represents months from randomization, and the Y-axis shows the survival percentage. A risk table below shows the number of subjects at risk at specific time points for both groups.*

FDA Label Image

1 (Abiraterone Acetate Tablets Usp 250 mg 500 mg 6)

Label for Abiraterone Acetate Tablets, USP 250 mg oral tablets by Amneal Pharmaceuticals NY LLC. The label includes active ingredient strength, dosage form, and warnings, with a count of 120 tablets. It specifies manufacturing and distribution information, storage conditions, and displays a barcode.*

FDA Label Image

1 (Abiraterone Acetate Tablets Usp 250 mg 500 mg 7)

Label for Abiraterone Acetate Tablets, USP 500 mg oral tablets. The label includes a brown, oval-shaped tablet imprint '1754' and states the product is Rx only with 60 tablets per package. Manufactured by Amneal Pharmaceuticals Private Limited, and distributed by Amneal Pharmaceuticals LLC. Storage instructions and barcode are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.